

Lapatinib EGF104900

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Lapatinib EGF104900

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR-metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChT  
 Experimental Arm: Lapatinib + Trastuzumab  
 Control Arm: Lapatinib



